

ESMO PRECEPTORSHIP

LISBON PORTUGAL 27-28 SEPTEMBER 2024

Co-Chairs

Sara Lonardi, Italy Florian Lordick, Germany



ESMO PRECEPTORSHIP PROGRAMME **GASTRIC CANCER**

Multidisciplinary management, standards of care. therapeutic targets and future perspectives

> Lisbon, Portugal 27-28 September 2024

CO-CHAIRS Sara Lonardi, Italy Florian Lordick, Germany

SPEAKERS Fátima Carneiro, Portugal Christelle de la Fouchardière, France Mário Dinis-Ribeiro, Portugal Matteo Fassan, Italy Tania Fleitas, Spain Guillaume Piessen, France

LEARNING OBJECTIVES

- To learn about the fundamentals of epidemiology, aetiology, pathogenesis, molecular events and immune biology of gastric and esophago-gastric junction cancer
- To understand the essentials in the diagnosis and multidisciplinary treatment of gastric cancer
- To learn about advances in the treatment and novel targets in gastric cancer

ACCREDITATION

The programme of this event has been accredited with 10 ESMO-MORA category 1 points.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an independent educational grant from





ORGANISATION AND CONTACTS

ESMO Head Office **Education Department** Via Ginevra 4 6900 Lugano Switzerland

Email: courses@esmo.org

www.esmo.org



Friday, 27 September 2024

| 09:00-09:10 10' | Opening and welcome | | |
|---------------------|---|---|--|
| 10' | Welcome from ESMO and introduction | Sara Lonardi, IT Florian Lordick, DE | |
| 09:10-10:50 100' | SESSION 1 Pathology and diagnosis of gastric cancer | Chair: Sara Lonardi, IT | |
| 20' | Gastric cancer as a global health problem | Florian Lordick, DE | |
| 30' | Pathology and classification of gastric cancer | Matteo Fassan, IT | |
| 30' | Practical skills for hereditary gastric cancer | Fátima Carneiro, PT | |
| 20' | Q&A | All | |
| 10:50-11:20 | Coffee break | | |
| 11:20-13:10 110' | SESSION 2 Early and locally advanced gastric and EG junction cancer | Chair: Florian Lordick, DE | |
| 30' | Endoscopic diagnosis and treatment of early gastric cancer | Mário Dinis-Ribeiro, PT | |
| 30' | Surgery for gastric and EG junction cancer | Guillaume Piessen, FR | |
| 30' | Neoadjuvant and perioperative treatment for locally advanced gastric cancer | Sara Lonardi, IT | |
| 20' | Q&A | All | |
| 13:10-14:10 | Lunch | | |
| 14:10-15:20 70' | SESSION 3 Break-out session: Oesophageal cancer and supportive care | Chairs: Christelle de la Fouchardière, FR Guillaume Piessen, FR | |
| 30' | Particular aspects in patients with squamous cell histology (peri-operative and advanced) | Florian Lordick, DE | |
| 30' | Comprehensive supportive care of oesophago-gastric cancer patients | Sara Lonardi, IT | |
| 10' | Q&A | All | |
| 15:20-15:50 | Coffee break | | |
| 15:50-17:20 90' | SESSION 4 Case discussion based on ESMO Clinical Practice Guidelines - Localised disease | Chairs: Sara Lonardi, IT Florian Lordick, DE | |
| 90' | Participants clinical case discussion (6x15') | Faculty | |
| 20:30 | Dinner | | |

Saturday, 28 September 2024

| 09:00-10:50 110' | SESSION 5 Advanced disease | Chairs: Matteo Fassan, IT Sara Lonardi, IT |
|-----------------------------------|---|--|
| 30' | Sequential chemotherapy (doublet, triplet, elderly patients, sequences, anti-angiogenic therapy, oral chemotherapy) | Tania Fleitas, ES |
| 30' | Biologically targeted treatment (HER2, Claudin 18.2, FGFR2, and beyond) | Florian Lordick, DE |
| 30' | Immunotherapy in adenocarcinoma | Christelle de la Fouchardière, FR |
| 20' | Q&A | All |
| | | |
| 10:50-11:20 | Coffee break | |
| 10:50-11:20 11:20-12:50 90' | SESSION 6 Case discussion based on ESMO Clinical Practice Guidelines - Advanced disease | Chair: Sara Lonardi, IT |
| 11:20-12:50 | SESSION 6 Case discussion based on ESMO Clinical Practice Guidelines - | |
| 11:20-12:50 90' | SESSION 6 Case discussion based on ESMO Clinical Practice Guidelines - Advanced disease | Sara Lonardi, IT |

Note: Each 15-minute slot for clinical case discussion includes a 7' case presentation and an 8' Q&A / panel discussion

esmo.org